Table 2.
Univariate and multivariate analysis of risk factors: relapse and death.
| Univariate analysis | Multivariate analysis | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Carcinoma—all | Carcinoma—skin | SCC—all | SCC—conjunctiva | Carcinoma—all | Carcinoma—skin | SCC—all | SCC—conjunctiva | |||||||||
| Relapse | Death | Relapse | Death | Relapse | Death | Relapse | Death | Relapse | Death | Relapse | Death | Relapse | Death | Relapse | Death | |
| Gender | 0.333 | 0.538 | 0.792 | 0.741 | 0.343 | 0.802 | 0.076 | 0.691 | ||||||||
| Site | 0.336 | 0.859 | 0.871 | 0.575 | 0.474 | 0.986 | 0.127 | 0.379 | ||||||||
| Localisation | 0.077 | 0.019 | 0.113 | 0.085 | 0.194 | 0.162 | 0.028 | |||||||||
| Relapse preop. | 0.226 | 0.562 | 0.730 | 0.888 | 0.546 | 0.763 | 0.641 | 0.823 | ||||||||
| Type of exenteration | 0.700 | 0.771 | 0.946 | 0.321 | 0.907 | 0.833 | 0.962 | 0.583 | ||||||||
| ND | 0.000 | 0.003 | 0.002 | 0.022 | 0.000 | 0.183 | 0.000 | 0.130 | 0.002 | 0.400 | 0.775 | 0.657 | 0.056 | 0.900 | ||
| Reconstruction | 0.631 | 0.777 | 0.772 | 0.436 | 0.304 | 0.138 | ||||||||||
| Time of reconstruction | 0.042 | 0.249 | 0.162 | 0.180 | 0.047 | 0.019 | 0.003 | 0.039 | 0.115 | |||||||
| T | 0.378 | 0.669 | 0.645 | 0.715 | 0.198 | 0.436 | 0.125 | 0.206 | ||||||||
| N | 0.000 | 0.004 | 0.000 | 0.013 | 0.000 | 0.435 | 0.003 | 0.215 | 0.592 | 0.063 | 0.089 | 0.817 | 0.292 | 0.025 | ||
| M | ||||||||||||||||
| G | 0.731 | 0.281 | 0.063 | 0.012 | 0.892 | 0.487 | 0.878 | 0.448 | 0.189 | |||||||
| L | 0.023 | 0.001 | 0.047 | 0.024 | 0.019 | 0.003 | 0.604 | 0.052 | 0.426 | 0.205 | 0.670 | 0.642 | 0.364 | 0.015 | ||
| PNI | 0.502 | 0.018 | 0.792 | 0.516 | 0.987 | 0.208 | – | – | 0.107 | |||||||
| Bone infiltration | 0.083 | 0.283 | 0.416 | 0.414 | 0.036 | 0.266 | 0.221 | |||||||||
| R | 0.000 | 0.002 | ||||||||||||||
| No. R0 | 0.388 | 0.448 | 0.910 | 0.955 | 0.987 | 0.371 | ||||||||||
| RTx pre | 0.582 | 0.785 | 0.515 | |||||||||||||
| CTx pre | ||||||||||||||||
| Adj. RTx | 0.586 | 0.852 | 0.297 | 0.703 | 0.544 | 0.761 | ||||||||||
| Adj. CTx | 0.502 | 0.429 | 0.059 | 0.148 | 0.447 | 0.680 | 0.192 | 0.296 | ||||||||
| Vision loss | 0.783 | 0.962 | 0.447 | 0.429 | 0.753 | 0.398 | 0.628 | 0.054 | ||||||||
| Pain | 0.905 | 0.104 | 0.679 | 0.233 | 0.724 | 0.670 | 0.907 | 0.509 | ||||||||
| Relapse | 0.505 | 0.281 | 0.989 | 0.534 | ||||||||||||
| Immunosuppression | 0.043 | 0.015 | 0.059 | 0.088 | 0.107 | 0.227 | 0.308 | 0.192 | 0.028 | 0.200 | ||||||
| Second tumour | 0.549 | 0.089 | 0.691 | 0.142 | 0.753 | 0.250 | ||||||||||
ND neck dissection, T extent of the primary tumour, N spread to regional lymph nodes, M presence of distant metastasis, G grade of the tumour, L invasion into lymphatic vessels, PNI perineural invasion, R resection boundaries, RTx pre history of preoperative radiotherapy, Adj. RTx/CTx adjuvant radiotherapy/chemotherapy.